Recent advances in treatment approaches to gaucher disease

Current Pharmaceutical Biotechnology

Volumn 12, Issue 6, 2011, Pages 854-860

  Elstein, Deborah ^a   Zimran, Ari ^a  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

Eliglustat tartrate; Enzyme replacement therapy; Gaucher disease; Imiglucerase; Isofagomine tartrate; Miglustat; Pharmacological chaperones; Substrate reduction therapy; Taliglucerase alfa; Velaglucerase alfa

Indexed keywords

AFEGOSTAT; ALGLUCERASE; AMBROXOL; DILTIAZEM; ELIGLUSTAT; GLUCOSYLCERAMIDASE; IMIGLUCERASE; MIGLUSTAT; TALIGLUCERASE ALFA; UNCLASSIFIED DRUG; UPLYS; VELAGLUCERASE ALFA;

ARTICLE; BLOOD BRAIN BARRIER; BONE MARROW TRANSPLANTATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; ENZYME REPLACEMENT; GAUCHER DISEASE; HUMAN; LIPID STORAGE; THROMBOCYTE COUNT; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

DRUG THERAPY, COMBINATION; ENZYME REPLACEMENT THERAPY; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HUMANS;

EID: 79956277751     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920111795542624     Document Type: Article

References (83)

1. Beutler, E.; Grabowski, G.A. Gaucher disease. In: The Metabolicand Molecular Basis of Inherited Disease; Scriver, C.R.; Beudet,A.L.; Sly, W.S., Eds. McGraw-Hill: New York, 2001, pp. 3635-3668.
2. Svennerholm, L.; Erikson, A.; Groth, C.G.; Ringdén, O.; Månsson, J. E. Norrbottnian type of Gaucher disease-Clinical, biochemicaland molecular biology aspects: Successful treatment with bonemarrow transplantation. Dev. Neurosci., 1991, 13,345-349.
3. Abrahamov, A.; Elstein, D.; Gross-Tsur, V. Farber, B.; Glaser, Y.; Hadas-Halpern, I.; Ronen, S.; Tafakjdi, M.; Horowitz, M.; Zimran, A. Gaucher's disease variant characterized by progressive calcificationof heart valves and unique genotype. Lancet, 1995, 346, 1000-1003.
4. Meikle, P.J.; Fuller, M.; Hopwood, J. J. Gaucher Disease: Epidemiologyand screening policy. In: Gaucher Disease, edited by Futerman, A. H.; Zimran. Eds., CRC Press, Florida, 2007, pp. 321.
5. Brady, R.O.; Kanfer, J.N.; Shapiro, D. Metabolism of glucocerebrosides:II. Evidence of an enzymatic deficiency in Gaucher's disease. Biochem. Biophys. Res. Commun., 1965, 18, 221-232.
6. Patrick, A.D. Short communications: A deficiency of glucocerebrosidasein Gaucher's disease. Biochem. J., 1965, 97,17C.
7. Hruska, K.S.; LaMarca, M.E.; Scott, C.R.; Sidransky, E. Gaucherdisease: mutation and polymorphism spectrum in the glucocerebrosidasegene (GBA). Hum. Mutat., 2008, 29(5), 567-583.
8. Goker-Alpan, O.; Hruska, K.S.; Orvisky, E.; Kishnani, P.S.; Stubblefield, B.K.; Schiffmann, R.; Sidransky, E. Divergent phenotypesin Gaucher disease implicate the role of modifiers. J. Med.Genet., 2005, 42(6), 37.
9. Azuri, J.; Elstein, D.; Lahad, A.; Abrahamov, A.; Hadas-Halpern, I.; Zimran, A. Asymptomatic Gaucher disease implications for large-scale screening. Genet. Test, 1998, 2, 297-299.
10. Fairley, C.; Zimran, A.; Phillips, M.; Cizmarik, M.; Yee, J.; Weinreb, N.; Packman, S. Phenotypic heterogeneity of N370S homozygoteswith type I Gaucher disease: an analysis of 798 patients fromthe ICGG Gaucher Registry. J. Inherit. Metab. Dis., 2008, 31(6),7387-7394.
11. Kaplan, P.; Andersson, H.C.; Kacena, K.A.; Yee, J.D. The clinicaland demographic characteristics of nonneuronopathic Gaucher diseasein 887 children at diagnosis. Arch. Pediatr. Adolesc. Med.,2006,160, 603-608.
12. Stowens, D.W.; Teitelbaum, S.L.; Kahn, A.J.; Barranger, J. Skeletalcomplications of Gaucher's disease. Medicine, 1985, 64, 310-322.
13. Hermann, G.; Goldblatt, J.; Levy, R.N.; Goldsmith, S.J.; Desnick, R.J.; Grabowski, G.A. Gaucher's disease type 1: assessment ofbone involvement by CT and scintigraphy. Am. J. Roentgenol.,1986, 147, 943-948.
14. Maas, M.; Hollak, C.E.; Akkerman, E.M.; Aerts, J.M.; Stoker, J.; Den Heeten, G.J. Quantification of skeletal involvement in adultswith type I Gaucher's disease: fat fraction measured by Dixonquantitative chemical shift imaging as a valid parameter. AJR. Am.J. Roentgenol., 2002, 179(4), 961-965.
15. Neudorfer, O.; Giladi, N.; Elstein, D.; Abrahamov, A.; Turezkie, T.; Aghai, E.; Reches, A.; Bembi, B.; Zimran, A. Occurrence of Parkinson's syndrome in type I Gaucher disease. Quar, J. Med.,1996, 89,691-694.
16. Bultron, G.; Kacen K.; Pearson, D.; Boxer, M.; Yang, R.; Sathe, S.; Pastores, G.; Mistry, P.K. The risk of Parkinson's disease in type 1 Gaucher disease. J. Inherit. Metab. Dis., 2010 Feb 23.
17. Pastores, G.M. Musculoskeletal complications encountered in thelysosomal storage disorders. Best Pract. Res. Clin. Rheumatol.,2008, 22(5), 937-947.
18. Biegstraaten, M.; van Schaik, I.N.; Aerts, J.M.; Hollak, C.E. 'Nonneuronopathic'Gaucher disease reconsidered. Prevalence of neurologicalmanifestations in a Dutch cohort of type I Gaucher diseasepatients and a systematic review of the literature. J. Inherit. Metab.Dis., 2008, 31(3), 337-349.
19. Brady, R.O.; Barton, N.W.; Grabowski, G.A. The role of neurogeneticsin Gaucher disease. Arch. Neurol., 1993, 50, 1212-1218.
20. Uyama, E.; Takahashi, K.; Owada, M.; Okamura, R.; Naito, M.; Tsuji, S.; Kawasaki, S.; Araki, S. Hydrocephalus, corneal opacities, deafness, valvular heart disease, deformed toes and leptomeningealfibrous thickening in adult siblings: A new syndrome associatedwith beta-glucocerebrosidase deficiency and a mosaic populationof storage cells. Acta Neurol. Scand., 1992, 86, 407-411.
21. Chabas, A.; Cormand, B.; Grinberg, D.; Burguera, J.M.; Balcells, S.; Merino, J.L.; Mate, I.; Sobrino, J.A.; Gonzàlez-Duarte, R.; Vilageliu, L. Unusual expression of Gaucher's disease: Cardiovascularcalcifications in three sibs homozygous for the D409H mutation. J. Med. Genet., 1995, 32, 740-746.
22. Dvir, H.; Harel, M.; McCarthy, A.A.; Toker, L.; Silman, I.; Futerman, A.H.; Sussman, J.L. X-ray structure of human acid-betaglucosidase,the defective enzyme in Gaucher disease. EMBO Rep.,2003, 4, 704-714.
23. Beutler, E.; Kuhl, W. The diagnosis of the adult type of Gaucher'sdisease and its carrier state by demonstration of deficiency of betaglucosidaseactivity in peripheral blood leukocytes. J. Lab. Clin.Med., 1970, 76, 747-751.
24. Rudensky, B.; Paz, E.; Altarescu, G.; Raveh, D.; Elstein, D.; Zimran, A. Fluorescent flow cytometric assay: a new diagnostic tool formeasuring beta-glucocerebrosidase activity in Gaucher disease. Blood Cells Mol. Dis., 2003, 30, 97-100.
25. DeDuve, C. From cytases to lysosomes. Fed. Proc., 1964, 23,1045-1049
26. Brady, R.O. The sphingolipidoses. N. Engl. J. Med., 1966, 275(6),312-318.
27. Barton, N.W.; Brady, R.O.; Dambrosia, J.M.; Di Bisceglie, A.M.; Doppelt, S.H.; Hill, S.C.; Mankin, H.J.; Murray, G.J.; Parker, R.I.; Argoff, C.E.; and collaborators. Replacement therapy for inheritedenzyme deficiency-Macrophage-targeted glucocerebrosidase forGaucher's disease. N. Engl. J. Med., 1991, 324, 1464-1468.
28. Grabowski, G.A.; Barton, N.W.; Pastores, G.; Dambrosia, J.M.; Banerjee, T.K.; McKee, M.A.; Parker, C.; Schiffmann, R.; Hill, S.C.; Brady, R.O. Enzyme therapy in type 1 Gaucher disease: comparativeefficacy of mannose-terminated glucocerebrosidase fromnatural and recombinant sources. Ann. Intern. Med., 1995, 122, 33-37.
29. Zimran, A.; Elstein, D.; Levy-Lahad, E.; Zevin, S.; Hadas-Halpern, I.; Bar-Ziv, Y.; Foldes, J.; Schwartz, A.J; Abrahamov, A. Replacementtherapy with imiglucerase for type 1 Gaucher's disease. Lancet,1995, 34, 1479-1480.
30. Weinreb, N.J.; Charrow, J.; Andersson, H.C.; Kaplan, P.; Kolodny, E.H.; Mistry, P.; Pastores, G.; Rosenbloom, B.E.; Scott, C.R.; Wappner, R.S.; Zimran, A. Effectiveness of enzyme replacementtherapy in 1028 patients with type 1 Gaucher disease after 2 to 5years of treatment: a report from the Gaucher Registry. Am. J.Med., 2002, 113, 112-118.
31. Brady, R.O. Enzyme replacement for lysosomal diseases. Annu.Rev. Med., 2006, 57, 283-284.
32. Zimran, A.; Bembi, B.; Pastores, G. Enzyme replacement therapyfor type I Gaucher disease. In: Gaucher disease, edited by Futerman,A.H.; Zimran, A. CRC Press, Florida, 2007, pp.341.
33. Grabowski, G.A.; Kacena, K.; Cole, J.A.; Hollak, C.E.; Zhang, L.; Yee, J.; Mistry, P.K.; Zimran, A.; Charrow, J.; vom Dahl, S. Doseresponserelationships for enzyme replacement therapy withimiglucerase/alglucerase in patients with Gaucher disease type 1.Genet. Med., 2009, 11, 92-99.
34. Charrow, J.; Andersson, H.C.; Kaplan, P.; Kolodny, E.H.; Mistry, P.; Pastores, G.; Rosenbloom, B.E.; Scott, C.R.; Wappner, R.S.; Weinreb, N.J.; Zimran, A. The Gaucher registry: demographics anddisease characteristics of 1698 patients with Gaucher disease. Arch.Intern. Med., 2000, 160(18), 2835-2843.
35. Weinreb, N. J. Advances in Gaucher disease: Therapeutic goals andevaluation and monitoring guidelines. Semin. Hematol., 2004, 41 (4Suppl 5),1-3.
36. Pastores, G. M.; Weinreb, N. J.; Aerts, H.; Andria, G.; Cox, T. M.; Giralt, M.; Grabowski, G. A.; Mistry, P. K.; Tylki-Szymańska, A. Therapeutic goals in the treatment of Gaucher disease. Semin. Hematol.,2004, 41(4 Suppl 5),4-14.
37. Weinreb, N.; Taylor, J.; Cox, T.; Yee, J.; vom Dahl, S. A benchmarkanalysis of the achievement of therapeutic goals for type 1Gaucher disease patients treated with imiglucerase. Amer. J. Hematol.,2008, 83(12), 890-895.
38. Rosenthal, D. I.; Doppelt, S. H.; Mankin, H. J.; Dambrosia, J. M.; Xavier, R. J.; McKusick, K. A.; Rosen, B. R.; Baker, J.; Niklason, L.T.; Hill, S. C.; and collaborators. Enzyme replacement therapyfor Gaucher disease: skeletal responses to macrophage-targetedglucocerebrosidase. Pediatrics, 1995, 96(4 Pt 1), 629-637.
39. Poll, L. W.; Maas, M.; Terk, M. R.; Roca-Espiau, M.; Bembi, B.; Ciana, G.; Weinreb, N.J. Response of Gaucher bone disease toenzyme replacement therapy. Br. J. Radiol., 2002, 75 (Suppl) 1,A25-A36.
40. de Fost, M.; Hollak, C. E.; Groener, J. E.; Aerts, J. M.; Maas, M.; Poll, L.W.; Wiersma, M. G.; Häussinger, D.; Brett, S.; Brill, N.; vom Dahl, S. Superior effects of high-dose enzyme replacementtherapy in type 1 Gaucher disease on bone marrow involvementand chitotriosidase levels: a 2-center retrospective analysis. Blood,2006, 108 (3), 830-835.
41. Fleshner, P. R.; Aufses, A. H. Jr.; Grabowski, G. A.; Elias, R. A27-year experience with splenectomy for Gaucher's disease. Am. J. Surg., 1991, 161(1), 69-75.
42. Zimran, A.; Elstein, D.; Schiffmann, R.; Abrahamov, A.; Goldberg, M.; Bar-Maor, J. A.; Brady, R. O.; Guzzetta, P. C.; Barton, N. W. Outcome of partial splenectomy for type I Gaucher disease. J. Pediatr.,1995, 126(4), 596-597.
43. Zimran, A., Abrahamov, A.; Elstein, D. Children with type I Gaucherdisease: growing into adulthood with and without enzymetherapy. Isr. Med. Assoc. J., 2000, 2(2), 80-81.
44. Mistry, P. K.; Sirrs, S.; Chan, A.; Pritzker, M.R.; Duffy, T. P.; Grace, M. E.; Meeker, D. P.; Goldman, M. E. Pulmonary hypertensionin type 1 Gaucher's disease: genetic and epigenetic determinantsof phenotype and response to therapy. Mol. Genet. Metab.,2002, 77, 91-98.
45. Bove, K. E.; Daugherty, C.; Grabowski, G. A. Pathological findingsin Gaucher disease type 2 patients following enzyme therapy. Hum. Pathol., 1995, 26(9), 1040-1045.
46. Davies, E. H.; Erikson, A.; Collin-Histed, T.; Mengel, E.; Tylki-Szymanska, A.; Vellodi, A. Outcome of type III Gaucher diseaseon enzyme replacement therapy: review of 55 cases. J. Inherit. Metab. Dis., 2007, 30(6), 935-942.
47. Altarescu, G.; Hill, S.; Wiggs, E.; Jeffries, N.; Kreps, C.; Parker, C.C.; Brady, R.O.; Barton, N. W.; Schiffmann, R. The efficacy of enzymereplacement therapy in patients with chronic neuronopathic Gaucher's disease. J. Pediatr., 2001, 138, 539-545.
48. Zimran, A.; Elstein, D. No justification for very high-dose enzymetherapy for patients with type III Gaucher disease. J. Inherit. Metab.Dis., 2007, 30, 843-844.
49. Starzyk, K.; Richards, S.; Yee, J.; Smith, S. E.; Kingma, W. The long-term international safety experience of imiglucerase therapyfor Gaucher disease. Mol. Genet. Metab., 2007, 90, 157-161.
50. Zhao, H.; Bailey, L. A.; Grabowski, G. A. Enzyme therapy ofgaucher disease: clinical and biochemical changes during productionof and tolerization for neutralizing antibodies. Blood, Cells Mol. Dis., 2003, 30(1), 90-96.
51. Zimran, A.; Hollak, C. E. M.; Abrahamov, A.; van Oers, M. H.; Kelly, M.; Beutler, E. Home treatment with intravenous enzymereplacement therapy for Gaucher disease: An international collaborativestudy of 33 patients. Blood, 1993, 82,1107-1109.
52. Elstein, D.; Granovsky-Grisaru, S.; Rabinowitz, R.; Kanai, R.; Abrahamov, A.; Zimran, A. Use of enzyme replacement therapyfor Gaucher disease during pregnancy. Am. J. Obstet. Gynecol.,1997, 177, 1509-1512.
53. Langeveld, M.; de Fost, M.; Aerts, J. M.; Sauerwein, H. P.; Hollak, C. E. Overweight, insulin resistance and type II diabetes in type IGaucher disease patients in relation to enzyme replacement therapy. Blood Cells Mol. Dis., 2008, 40(3), 428-432.
54. Rosenbloom, B. E.; Weinreb, N. J.; Zimran, A.; Kacena, K. A.; Charrow, J.; Ward, E. Gaucher disease and cancer incidence: astudy from the Gaucher Registry. Blood, 2005, 105, 4569-4572.
55. Erjavec, Z.; Hollak, C. E.; de Vries, E. G. Hepatocellular carcinomain a patient with Gaucher disease on enzyme supplementationtherapy. Ann. Oncol., 1999, 10(2), 243.
56. Margalit, M.; Shalev, Z.; Pappo, O.; Sklair-Levy, M.; Alper, R.; Gomori, M.; Engelhardt, D.; Rabbani, E.; Ilan, Y. Glucocerebrosideameliorates the metabolic syndrome in OB/OB mice. J.Pharmacol. Exp. Ther., 2006, 319, 105-110.
57. Lalazar, G.; Preston, S.; Zigmond, E.; Ben Yáacov, A.; Ilan, Y. Glycolipids as immune modulatory tools. Mini Rev. Med. Chem.,2006, 6(11), 1249-1253.
58. Ilan, Y.; Elstein, D.; Zimran, A. Glucocerebroside: an evolutionaryadvantage for patients with Gaucher disease and a new immunomodulatoryagent. Immunol. Cell Biol., 2009, 87(7), 514-524.
59. Zimran, A.; Loveday, K.; Fratazzi, C.; Elstein, D. A pharmacokineticanalysis of a novel enzyme replacement therapy with Gene-Activated human glucocerebrosidase (GA-GCB) in patients with type 1 Gaucher disease. Blood Cells Mol. Dis., 2007, 39, 115-117.
60. Aviezer, D.; Brill-Almon, E.; Shaaltiel Y.; Hashmueli, S.; Bartfeld, D.; Mizrachi, S.; Liberman, Y.; Freeman, A.; Zimran, A.; Galun, E.A plant-derived recombinant human glucocerebrosidase enzyme--apreclinical and phase I investigation. PLoS ONE, 2009, 4792, 4e.
61. Hollak, C. E.; vom Dahl, S.; Aerts, J. M., Belmatoug, N.; Bembi, B.; Cohen, Y.; Collin-Histed, T.; Deegan, P.; van Dussen, L.; Giraldo, P.; Mengel, E.; Michelakakis, H.; Manuel, J.; Hrebicek, M.; Parini, R.; Reinke, J.; di Rocco, M.; Pocovi, M.; Sa Miranda, M.C.; Tylki-Szymanska, A.; Zimran, A.; Cox, T. M. Force Majeure:therapeutic measures in response to restricted supply ofimiglucerase (Cerezyme) for patients with Gaucher disease. Blood Cells Mol. Dis., 2010, 44(1),41-47.
62. Zimran, A.; Altarescu, G.; Phillips, M.; Attias, D.; Jmoudiak, M.; Deeb, M.; Wang, N.; Bhirangi, K.; Cohn, G. M.; Elstein, D. Phase I/II and extension study of velaglucerase alfa (Gene-Activated™Human Glucocerebrosidase) replacement therapy in adults withtype 1 gaucher disease: 48 month experience. Blood, 2010,115(23), 4651-4656.
63. Aviezer, D.; Almon-Brill, E.; Shaaltiel, Y.; Chertkoff, R.; Hashmueli, S.; Zimran, A. Novel enzyme replacement therapy forGaucher disease: Phase III pivotal clinical trial with plant cell expressedrecombinant glucocerebrosidase (prGCD)- taliglucerase alpha. 6th Annual WORLD Symposium 2010, Miami FL, February10-12, 2010.
64. Radin, N.S. Chemical models and chemotherapy in the sphingolipidoses, in Current Trends in Sphingolipidoses and Allied Disorders, Ed.; Volk, B.W.; Schneck, L. Plenum Press, New York,1976, pp. 453-465.
65. Cox, T.; Lachmann, R.; Hollak, C.; Aerts, J.; van Weely, S.; Hrebicek, M.; Platt, F.; Butters, T.; Dwek, R.; Moyses, C.; Gow. I.; Elstein, D.; Zimran, A. Novel oral treatment of Gaucher's diseasewith N-butyldeoxynojirimycin (OGT 918) to decrease substratebiosynthesis. Lancet, 2000, 355, 1481-1485.
66. Heitner, R.; Elstein, D.; Aerts, J.; van Weely, S.; Zimran, A. LowdoseN-butyldeoxynojirimycin (OGT 918) for type I Gaucher disease. Blood Cells Mol. Dis., 2002, 28, 127-129.
67. Elstein, D.; Dweck, A.; Attias, D.; Hadas-Halpern, I.; Zevin, S.; Altarescu, G.; Aerts, J.F.; van Weely, S.; Zimran, A. Oral maintenanceclinical trial with miglustat for type I Gaucher disease:switch from or combination with intravenous enzyme replacement. Blood, 2007, 110, 2296-2299.
68. Giraldo, P.; Alfonso, P.; Atutxa, K.; Fernández-Galán, M.A.; Barez, A.; Franco. R.; Alonso, D.; Martin, A.; Latre, P.; Pocovi, M. Real-world clinical experience with long-term miglustat maintenancetherapy in type 1 Gaucher disease: the ZAGAL project. Haematologica, 2009, 94(12), 1771-1775.
69. Watman, N.; Arreguin, E.A.; Pastores, G.; Iastrebner, M.; Dragosky, M.; Rosenbaum, H.; Phillips, M.; Kaper, M.; Singh, T.; Puga, A.C. Bone response to GENZ-112638 in a Phase 2 study inGaucher disease type 1. 6th Annual WORLD Symposium 2010,Miami FL, February 10-12.
70. Sawkar, A.R.; Cheng, W.C.; Beutler, E.; Wong, C.H.; Balch, W.E.; Kelly, J.W. Chemical chaperones increase the cellular activity ofN370S beta -glucosidase: a therapeutic strategy for Gaucher disease. Proc. Natl. Acad. Sci. USA, 2002, 99(24), 15428-15433.
71. Ron, I.; Horowitz, M. ER retention and degradation as the molecularbasis underlying Gaucher disease heterogeneity. Hum. Mol.Genet., 2005, 14, 2387-2398.
72. Desnick, R.J. Enzyme replacement therapy for Fabry disease: lessonsfrom two alpha-galactosidase A orphan products and one FD A approval. Expert Opin. Biol. Ther., 2004, 4(7),1167-1176.
73. Chang, H.H.; Asano, N.; Ishii, S.; Ichikawa, Y.; Fan, J.Q. Hydrophiliciminosugar active-site-specific chaperones increase residualglucocerebrosidase activity in fibroblasts from Gaucher patients. FEBS J., 2006, 273(17),4082-4092.
74. Shen, J.S.; Edwards, N.J.; Hong, Y.B.; Murray, G.J. Isofagomineincreases lysosomal delivery of exogenous glucocerebrosidase. Biochem. Biophys. Res. Commun., 2008, 369(4),1071-1075.
75. Khanna, R.; Benjamin, E.R.; Pellegrino, L.; Schilling, A.; Rigat, B.A.; Soska, R.; Nafar, H.; Ranes, B.E.; Feng, J.; Lun, Y.; Powe, A.C.; Palling, D.J.; Wustman, B.A.; Schiffmann, R.; Mahuran, D.J.; Lockhart, D.J.; Valenzano, K.J. The pharmacological chaperoneisofagomine increases the activity of the Gaucher diseaseL444P mutant form of beta-glucosidase. FEBS J., 2010,277(7),1618-1638.
76. Tropak, M.B.; Kornhaber, G.J.; Rigat, B.A.; Maegawa, G.H.; Buttner, J.D.; Blanchard, J.E.; Murphy, C.; Tuske, S.J.; Coales, S.J.; Hamuro, Y.; Brown, E.D.; Mahuran, D.J. Identification ofpharmacological chaperones for Gaucher disease and characterizationof their effects on beta-glucocerebrosidase by hydrogen/deuterium exchange mass spectrometry. Chembiochem., 2008,9(16), 2650-2662.
77. Maegawa, G.H.; Tropak, M.B.; Buttner, J.D.; Rigat, B.A.; Fuller, M.; Pandit, D.; Tang, L.; Kornhaber, G.J.; Hamuro, Y.; Clarke, J.T.; Mahuran, D.J. Identification and characterization of ambroxolas an enzyme-enhancement agent for Gaucher disease. J. Biol.Chem., 2009, 284(35), 23502-23516.
78. Ratjen, F.; Wönne, R.; Posselt, H.G.; Stöver, B.; Hofmann, D.; Bender, S.W. A double-blind placebo controlled trial with oral ambroxoland N-acetylcysteine for mucolytic treatment in cystic fibrosis. Eur. J. Pediatr., 1985, 144(4), 374-378.
79. Laoag-Fernandez, J. B.; Fernandez, A. M.; Maruo, T. Antenatal useof ambroxol for the prevention of infant respiratory distress syndrome.J. Obstet. Gynaecol. Res., 2000, 26(4),307-312.
80. Rigat, B.; Mahuran, D. Diltiazem, a L-type Ca(2+) channelblocker, also acts as a pharmacological chaperone in Gaucher patientcells. Mol. Genet. Metab., 2009, 96(4),225-232.
81. Capablo, J. L.; Franco, R.; de Cabezón, A. S.; Alfonso, P.; Pocovi, M.; Giraldo, P. Neurologic improvement in a type 3 Gaucher diseasepatient treated with imiglucerase/miglustat combination. Epilepsia, 2007, 48(7), 1406-1408.
82. Wenstrup, R. J.; Bailey, L.; Grabowski, G. A.; Moskovitz, J.; Oestreich, A. E.; Wu, W.; Sun, S. Gaucher disease: alendronatedisodium improves bone mineral density in adults receiving enzymetherapy. Blood, 2004, 104(5), 1253-1257.
83. Mikosch, P.; Reed, M.; Stettner, H.; Baker, R.; Mehta, A. B.; Hughes, D. A. Patients with Gaucher disease living in Englandshow a high prevalence of vitamin D insufficiency with correlationto osteodensitometry. Mol. Genet. Metab., 2009, 96(3),113-120.